Clinical trials: Psychomotor Agitation
Alzheimer's Disease
A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Active treatment extension study of the 331-14-213 trial, to assess the long-term safety and tolerability of oral brexpiprazole as treatment in adult participants with agitation associated with dementia of the Alzheimer's type…
- Trial name
- NCT03594123
- Testing
- Brexpiprazole
- Where
- United States
- Volunteers
- 259 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Child Behavior Disorders
The Inner Garden and Care for Children With Moderate to Severe Agitation
The objective is to compare the care including the solution of ambient sensory biofeedback "Inner Garden", compared to the care without this solution, on the regulation of behavioral disorders during a crisis requiring to take…
- Trial name
- ESSAIMS (NCT04610281)
- Testing
- Inner Garden
- Where
- France
- Volunteers
- 63 people
- Sponsor
- Groupe Hospitalier de la Rochelle Ré Aunis
Delirium, Agitation
Effects of Dexmedetomidine on Delirium Duration of Non-intubated ICU Patients (4D Trial)
The primary purpose of the study is to evaluate whether dexmedetomidine is effective in treating agitated delirium of non-intubated ICI patients
- Trial name
- 4D (NCT03317067)
- Testing
- Dexmedetomidine
- Where
- France
- Volunteers
- 168 people
- Sponsor
- University Hospital, Clermont-Ferrand
Alzheimer's Disease
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
The primary purpose of this study is to determine whether ELND005 is effective in treating symptoms of agitation and aggression in patients with Alzheimer's disease
- Trial name
- NCT01735630
- Testing
- ELND005
- Where
- 70 sites in United States, Canada and 2 more
- Volunteers
- 350 people
- Sponsor
- OPKO Health, Inc.
Agitation, Anesthesia
Use of Dexmedetomidine to Reduce Emergence Delirium Incident in Children
Emergence delirium (ED) from general anesthesia posts risk and harm to pediatric population undergo general anesthesia. The purpose of the study is to compare the use of dexmedetomidine versus placebo in reducing the incidence…
- Conditions
- Agitation, Anesthesia, Pediatrics
- Trial name
- DexPeds (NCT00857727)
- Testing
- Dexmedetomidine, Saline
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- St. Luke's-Roosevelt Hospital Center
Entropion
The Effect of Preoperative Ketamine on the Emergence Characteristics in Children Undergoing Entropion Surgery
The investigators evaluate extubation time and recovery profiles in children undergoing entropion surgery.
- Trial name
- NCT02916407
- Testing
- Sevoflurane, Desflurane
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- Inje University
Agitation,Psychomotor, Haloperidol Causing Adverse Effects in Therapeutic Use
Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation
The primary objective of this study is to determine the noninferiority of inhaled loxapine compared to intramuscular haloperidol/lorazepam on agitation reduction at 120 minutes.
- Conditions
- Agitation,Psychomotor, Haloperidol Causing Adverse Effects in Therapeutic Use, Lorazepam Causing Adverse Effects in Therapeutic Use, Loxapine Causing Adverse Effects in Therapeutic Use
- Trial name
- loxapine (NCT03110900)
- Testing
- Haloperidol + lorazepam, Loxapine
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Alzheimer's Disease, Psychosis
Treatment of Psychosis and Agitation in Alzheimer's Disease
Clinically, many patients with AD show no response or minimal response to antipsychotics for symptoms of agitation/aggression or psychosis, or they have intolerable side effects on these medications.
- Conditions
- Alzheimer's Disease, Psychosis, Agitation
- Trial name
- NCT02129348
- Testing
- Lithium
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- New York State Psychiatric Institute